Scaling GMP Cell Manufacturing
The CCT Manufacturing team is focused on expanding Stanford's cell manufacturing capacity and innovating cost-effective enhancements to improve the availability and performance of CAR-T cells.
Pioneering Closed Manufacturing Systems
We launched the first CCT investigator-initiated clinical trial using an automated, fully closed manufacturing platform. The CCT was also the first to adapt this system for retroviral transduction of CAR-T cells, and we have now successfully generated GD2 CAR-T cells using this process that are under study in a clinical trial for childhood brain tumors.
CCT is exploring novel, automated cell manufacturing approaches that have the capacity for cell selection, product monitoring during manufacturing, and scaling. These platforms hold promise for enhancing cell potency as well as manufacturing efficiency.